Provided by Tiger Trade Technology Pte. Ltd.

Heat Biologics

2.38
0.0000
Volume:- -
Turnover:104.61K
Market Cap:61.05M
PE:-1.69
High:2.38
Open:2.38
Low:2.38
Close:2.38
52wk High:10.85
52wk Low:2.07
Shares:25.65M
Float Shares:24.29M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4077
EPS(LYR):-1.4077
ROE:-31.12%
ROA:-17.10%
PB:0.54
PE(LYR):-1.69

Loading ...

Company Profile

Company Name:
Heat Biologics
Exchange:
AMEX
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Heat Biologics, Inc., a biopharmaceutical company, engages in the development of immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130 that is in phase I clinical trial for the treatment of advanced solid tumors. Its preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25; TNFRSF25 modulators for various immunotherapy approaches; and COVID-19 vaccine. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.